Literature DB >> 30860119

ISNO consensus guidelines for practical adaptation of the WHO 2016 classification of adult diffuse gliomas.

Vani Santosh1, Palavalasa Sravya2, Tejpal Gupta3, Dattatraya Muzumdar4, Geeta Chacko5, Vaishali Suri6, Sridhar Epari7, Anandh Balasubramaniam8, Bishan Dass Radotra9, Sandip Chatterjee10, Chitra Sarkar6, Rakesh Jalali11.   

Abstract

INTRODUCTION: Recent advances in the molecular biology of adult diffuse gliomas have brought about a paradigm shift in their diagnostic criteria, as witnessed in the World Health Organization (WHO) 2016 guidelines for central nervous system tumors. It is now mandatory to perform several molecular tests to reach a definitive integrated diagnosis in most of the cases. This comes with additional cost and higher turnaround time, which is not always affordable in developing countries like India. In addition, the non-uniform distribution of advanced research and diagnostic testing centers adds to the difficulty.
METHODS: The Indian Society of Neuro-oncology (ISNO) multidisciplinary expert panel consisting of neuropathologists, neurosurgeons, and radiation/medical oncologists convened to prepare the national consensus guidelines for approach to diagnosis of adult diffuse gliomas.
RESULTS: Algorithms for arriving at an integrated diagnosis of adult diffuse gliomas predominantly using immunohistochemistry and with minimum possible additional molecular testing were agreed upon, thus addressing the problems of cost, accessibility, and turnaround time. Mandatory and optional tests were proposed for each case scenario.
CONCLUSION: This document represents the consensus of the various neuro-oncology disciplines involved in diagnosis and management of patients with adult diffuse gliomas. The article reflects a practical adaptation of the WHO recommendations to suit a resource constrained setup.

Entities:  

Keywords:  Consensus guidelines; diagnosis; diffuse glioma; management

Mesh:

Year:  2019        PMID: 30860119     DOI: 10.4103/0028-3886.253572

Source DB:  PubMed          Journal:  Neurol India        ISSN: 0028-3886            Impact factor:   2.117


  8 in total

1.  Changing paradigms for targeted therapies against diffuse infiltrative gliomas: tackling a moving target.

Authors:  Candice D Carpenter; Iyad Alnahhas; Javier Gonzalez; Pierre Giglio; Vinay K Puduvalli
Journal:  Expert Rev Neurother       Date:  2019-05-27       Impact factor: 4.618

2.  Imaging-based stratification of adult gliomas prognosticates survival and correlates with the 2021 WHO classification.

Authors:  Akshaykumar N Kamble; Nidhi K Agrawal; Surabhi Koundal; Salil Bhargava; Abhaykumar N Kamble; David A Joyner; Tuba Kalelioglu; Sohil H Patel; Rajan Jain
Journal:  Neuroradiology       Date:  2022-07-25       Impact factor: 2.995

3.  Letter regarding Louis et al: The 2021 WHO Classification of Tumors of the Central Nervous System: A summary.

Authors:  Jigishaa Moudgil-Joshi; Chandrasekaran Kaliaperumal
Journal:  Neuro Oncol       Date:  2021-12-01       Impact factor: 13.029

4.  Response to letter to the editor by Moudgil-Joshi and Kaliaperumal.

Authors:  David N Louis; Ian A Cree
Journal:  Neuro Oncol       Date:  2021-12-01       Impact factor: 13.029

Review 5.  Mechanisms of Long Non-Coding RNAs in Biological Characteristics and Aerobic Glycolysis of Glioma.

Authors:  Ningning Zhao; Jiajie Zhang; Qian Zhao; Chao Chen; Huijuan Wang
Journal:  Int J Mol Sci       Date:  2021-10-18       Impact factor: 5.923

6.  Evaluation of the reporting quality of clinical practice guidelines on gliomas using the RIGHT checklist.

Authors:  Yongjie Yang; Yanfang Ma; Jingli Lu; Shuzhang Du; Jingmin Zhang; Haiyang Meng; Zhe Chen; Qiwen Zhang; Xiaojian Zhang; Wenyin Shi; Francesco Girolamo; Santiago Cepeda; Jian Kang
Journal:  Ann Transl Med       Date:  2021-06

Review 7.  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Pieter Wesseling; Daniel J Brat; Ian A Cree; Dominique Figarella-Branger; Cynthia Hawkins; H K Ng; Stefan M Pfister; Guido Reifenberger; Riccardo Soffietti; Andreas von Deimling; David W Ellison
Journal:  Neuro Oncol       Date:  2021-08-02       Impact factor: 13.029

8.  A novel Cas9-targeted long-read assay for simultaneous detection of IDH1/2 mutations and clinically relevant MGMT methylation in fresh biopsies of diffuse glioma.

Authors:  Thidathip Wongsurawat; Piroon Jenjaroenpun; Annick De Loose; Duah Alkam; David W Ussery; Intawat Nookaew; Yuet-Kin Leung; Shuk-Mei Ho; John D Day; Analiz Rodriguez
Journal:  Acta Neuropathol Commun       Date:  2020-06-20       Impact factor: 7.578

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.